Skip to main content

Research

Research

Risk for reduced bone mineral density in patients with ulcerative colitis

Patients with ulcerative colitis (UC) have reduced bone mineral density (BMD), regardless of steroid use, according to results from a meta-analysis.

In order to assess the relationship between UC and BMD, the investigators collected data from 13 cross-sectional studies published before August 2019 by searching PubMed, EMBASE, and the Cochrane Library. The meta-analysis comprised 570 patients with UC and 584 control individuals. The included studies, when pooled, indicated a decrease in BMD in patients with UC on the […]

Read more

Research

A protein that controls inflammation

A study has unraveled a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.

Inflammatory autoimmune diseases Inflammatory autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, psoriasis, and multiple sclerosis are amongst the most common diseases. Their prevalence has been rapidly expanding over the last few decades, which means that currently millions of patients are under constant treatment with anti-inflammatory drugs to keep their condition under control. As […]

Read more

Research

Air pollution exposure takes a heavy toll on gut bacteria

Breathing dirty air takes a heavy toll on gut bacteria, boosting risk of obesity, diabetes, gastrointestinal disorders and other chronic illnesses, new CU Boulder research suggests.

The study, published online in the journal Environment International, is the first to link air pollution to changes in the structure and function of the human gut microbiome—the collection of trillions of microorganisms residing within us. The gaseous pollutant ozone, which helps make up Denver’s infamous “brown cloud”—is particularly hazardous, the study found, with young adults exposed […]

Read more

News

Trial implicates MAP as treatable cause of Crohn’s disease

Posted: March 13 2020

The drug, a fixed-dose combination of clarithromycin, rifabutin and clofazimine (RHB-104, RedHill Biopharma) is yet to be approved for Crohn’s. However, the findings strengthen the case that MAP infection may be the cause of at least some cases of the disease. Infection with MAP has been a suspected, if controversial, cause of Crohn’s since the disease was […]

Read more

News

Using artificial intelligence to assess ulcerative colitis

Posted: March 12 2020

Assessments of patients with ulcerative colitis (UC), which is a type of inflammatory bowel disease, are usually conducted via endoscopy and histology. But now, researchers from Japan have developed a system that may be more accurate than existing methods and may reduce the need for these patients to undergo invasive medical procedures. In a study […]

Read more

News

Etrasimod offers orally delivered therapy option in UC

Posted: March 4 2020

In the study, researchers randomly assigned patients to 12 weeks of therapy with 1 mg or 2 mg once-daily etrasimod (APD334, Arena Pharmaceuticals) or placebo. Patients had a modified Mayo score between 4 and 9, endoscopic subscores of at least 2 and rectal bleeding subscores of at least 1. The primary endpoint was an increase in the […]

Read more

Research

The fate decision between pathogenic and regulatory T cells

Patients with inflammatory bowel disease have an imbalance between two types of immune system T cells.

Destructive Th17 cells that mediate chronic inflammation are elevated, and regulatory T cells, or Treg cells, which suppress inflammatory responses and play a protective role in autoimmune disorders, are diminished. Both cells differentiate from the same precursors — naïve CD4 T cells — and the beginning of their change to either Th17 or Treg cells […]

Read more

News

Striking differences in patients’ and physicians’ treatment goals and disease management expectations

Posted: February 20 2020

The IBD Global Assessment of Patient and Physician Unmet Needs Survey (IBD GAPPS) captured insights and perspectives from more than 2,000 patients and 600 physicians, exploring the physician-patient relationship, how patients and physicians define remission, their treatment expectations and levels of satisfaction with current therapies, as well as the impact of ulcerative colitis (UC) and […]

Read more

News

Don’t hate your guts – heal them

Posted: February 18 2020

Each one of us carries about 38 trillion bacteria around with us in our gut every day – if you wanted to count them all, it would take you more than a million years. How can such a veritable zoo of microbes reside peacefully in our guts without triggering our immune systems to attack them, […]

Read more

News

Scientists examine how a gut infection may produce chronic symptoms

Posted: February 18 2020

Keeping inflammation in checkIn a healthy gut, the immune system must strike a careful balance between responding to threats and keeping that response in check to avoid damage.“Inflammation helps the gut ward off an infection, but too much of it can cause lasting harm,” says Daniel Mucida, an associate professor and head of the Laboratory of Mucosal […]

Read more